
 
 
 
 
 
 
 
 
 What is claimed is: 
   
 1. A polypeptide consisting of an amino acid sequence as recited in SEQ. I.D. NO. 67, wherein the amino acid sequence as recited in SEQ. I.D. NO. 67 is substituted by at least one substitution selected from the following substitutions (i) to (iii); (i) substitution of Arg at residue 7, counting from the amino-terminus, by an amino acid selected from the group consisting of Ala, Asp, Asn, Gln, Ile, Leu, Met, Phe, Val, Glu and Ser;   (ii) substitution of Gln at residue 15, counting from the amino-terminus, by an amino acid selected from the group consisting of Arg and Lys; and   (iii) substitution of Tyr at residue 42, counting from the amino-terminus, by Asp or Glu.   
 
     
 2. The polypeptide according to claim 1, wherein the polypeptide has at least one activity selected from the group consisting of a trypsin inhibiting activity, a FXa inhibiting activity and an elastase inhibiting activity. 
 
     
 3. The polypeptide of claim 1, further having an amino terminal polypeptide having an amino acid sequence selected from the group consisting of: Asp-Asp-Ala-Ala-, Thr-Val-Ala-Ala-, Val-Ala-Ala-, Ala-Ala-, and Ala-.   
 
     
 4. The polypeptide of claim 3, further having a carboxy-terminal polypeptide having an amino acid sequence selected from the group consisting of: Gly-Val-Pro-Gly-Asp-Gly-Asp-Glu-Glu-Leu-Leu-Arg-Phe-Ser-Asn,   Gly-Val-Pro-Gly-Asp-Gly-Asp-Glu-Glu-Leu-Leu-Arg-Phe-Ser,   Gly-Val-Pro-Gly-Asp-Gly-Asp-Glu-Glu-Leu-Leu-Arg-Phe,   Gly-Val-Pro-Gly-Asp-Gly-Asp-Glu-Glu-Leu-Leu-Arg,   Gly-Val-Pro-Gly-Asp-Gly-Asp-Glu-Glu-Leu-Leu,   Gly-Val-Pro-Gly-Asp-Gly-Asp-Glu-Glu-Leu,   Gly-Val-Pro-Gly-Asp-Gly-Asp-Glu-Glu,   Gly-Val-Pro-Gly-Asp-Gly-Asp-Glu,   Gly-Val-Pro-Gly-Asp-Gly-Asp,   Gly-Val-Pro-Gly-Asp-Gly, Gly-Val-Pro-Gly-Asp,   Gly-Val-Pro-Gly, Gly-Val-Pro, Gly-Val, and Gly.   
 
     
 5. The polypeptide of claim 1, further having a carboxy-terminal polypeptide having an amino acid sequence selected from the group consisting of: Gly-Val-Pro-Gly-Asp-Gly-Asp-Glu-Glu-Leu-Leu-Arg-Phe-Ser-Asn,   Gly-Val-Pro-Gly-Asp-Gly-Asp-Glu-Glu-Leu-Leu-Arg-Phe-Ser,   Gly-Val-Pro-Gly-Asp-Gly-Asp-Glu-Glu-Leu-Leu-Arg-Phe,   Gly-Val-Pro-Gly-Asp-Gly-Asp-Glu-Glu-Leu-Leu-Arg,   Gly-Val-Pro-Gly-Asp-Gly-Asp-Glu-Glu-Leu-Leu,   Gly-Val-Pro-Gly-Asp-Gly-Asp-Glu-Glu-Leu,   Gly-Val-Pro-Gly-Asp-Gly-Asp-Glu-Glu,   Gly-Val-Pro-Gly-Asp-Gly-Asp-Glu,   Gly-Val-Pro-Gly-Asp-Gly-Asp,   Gly-Val-Pro-Gly-Asp-Gly, Gly-Val-Pro-Gly-Asp,   Gly-Val-Pro-Gly, Gly-Val-Pro, Gly-Val, and Gly.   
 
   
 
 
 
 
 
 
 
 
